Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: A systematic literature review

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 9, 2015, Pages 897-905

  Bazelier, Marloes T ^a   Eriksson, Irene ^b   de Vries, Frank ^a,c   Schmidt, Marjanka K ^d   Raitanen, Jani ^e,f   Haukka, Jari ^g   Starup Linde, Jakob ^h,i   De Bruin, Marie L ^a   Andersen, Morten ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h AALBORG UNIVERSITY   (Denmark)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Analysis techniques; Data management; Multi database; Pharmacoepidemiology; Systematic review

Indexed keywords

ARTICLE; DATA ANALYSIS; DRUG EXPOSURE; HUMAN; INFORMATION PROCESSING; META ANALYSIS (TOPIC); PATIENT CODING; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SYSTEMATIC REVIEW; CASE CONTROL STUDY; COHORT ANALYSIS; FACTUAL DATABASE; PROCEDURES; STATISTICS; TRENDS;

CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; HUMANS; PHARMACOEPIDEMIOLOGY; STATISTICS AS TOPIC;

EID: 84940930388     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3828     Document Type: Article

References (31)

1. The observational medical outcomes partnership. 2009; Available at: http://www.omop.fnih.org [14 April 2015].
2. The mini-sentinel program. 2010; Available at: http://www.mini-sentinel.org [14 April 2015].
3. The HMO research network. 2013; Available at: http://www.hmoresearchnetwork.org [14 April 2015].
4. Suissa S, Henry D, Caetano P, et al. Canadian Network for Observational Drug Effect Studies (CNODES). CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012; 6(4): e134-e140.
5. The Canadian Network for Observational Drug Effect Studies. 2013; Available at: http://www.cnodes.ca [14 April 2015].
6. The EU-ADR project. (2008) Available at: http://euadr-project.org [14 April 2015].
7. The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT). 2009; Available at: http://www.imi-protect.eu [14 April 2015].
8. AsPEN collaborators, Andersen M, Bergman U, et al. The Asian Pharmacoepidemiology Network (AsPEN): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf 2013; 22(7): 700-704.
9. Trifirò G, Mokhles MM, Dieleman JP, et al. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. Drug Saf 2012; 35(2): 159-171.
10. Mokhles MM, Trifirò G, Dieleman JP, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease. Pharmacol Res 2012; 65(3): 358-364.
11. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012.
12. Stephansson O, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013; 309(1): 48-54.
13. Bazelier MT, de Vries F, Vestergaard P, et al. Risk of fracture with thiazolidinediones: an individual patient data meta-analysis. Front Endocrinol (Lausanne) 2013; 4(11): 1-9.
14. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18(3): 246-252.
15. Coloma PM, Schuemie MJ, Trifirò G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011; 20(1): 1-11.
16. Davis RL, Rubanowice D, McPhillips H, et al. Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16(10): 1086-1094.
17. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013; 346: f880.
18. Engelter ST, Soinne L, Ringleb P, et al. IV thrombolysis and statins. Neurology 2011; 77(9): 888-895.
19. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63(4): 552-558.
20. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306(24): 2673-2683.
21. Hagiwara M, Delea TE, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc 2010; 31(3): 203-210.
22. Henk HJ, Teitelbaum A, Perez JR, Kaura S. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. Am J Hematol 2012; 87(5): 490-495.
23. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009; 120(23): 2322-2329.
24. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2(3): 155-163.
25. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012; 169(2): 178-185.
26. Schwartz GF, Kotak S, Mardekian J, Fain JM. Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases. BMC Ophthalmol 2011; 11: 14.
27. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172(20): 1582-1589.
28. Toh S, Baker MA, Brown JS, Kornegay C, Platt R, Mini-Sentinel Investigators. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. JAMA Intern Med 2013; 173(9): 817-819.
29. Tsai TT, Ho PM, Xu S, et al. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv 2010; 3(3): 230-235.
30. van Soest EM, Valkhoff VE, Mazzaglia G, et al. Suboptimal gastroprotective coverage of NSAID use and the risk of upper gastrointestinal bleeding and ulcers: an observational study using three European databases. Gut 2011; 60(12): 1650-1659.
31. Toh S, Reichman ME, Houstoun M, et al. Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. Pharmacoepidemiol Drug Saf 2013; 22(11): 1171-1177.